Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.42 is 79% above its 4-year average of -2.02, near the high end of its 4-year range (-4.64–-0.34).
20.00% below its 12-month average of -0.35.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.13.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 21 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.42
EARNINGS PER SHARE (EPS) AVG TTM
-0.35
EARNINGS PER SHARE (EPS) AVG 3Y
-1.36
EARNINGS PER SHARE (EPS) AVG 5Y
-2.02
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-20.00%
CURRENT VS 3Y AVG
+69.12%
CURRENT VS 5Y AVG
+79.17%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Taysha Gene Therapies, Inc.
Market Cap
$1.40B
Earnings Per Share (EPS)
-0.42
TTM Avg
-0.35
3Y Avg
-1.36
5Y Avg
-2.02
Market Cap
$1.40B
Earnings Per Share (EPS)
N/A
TTM Avg
-1.26
3Y Avg
-1.26
5Y Avg
-1.26
Market Cap
$1.40B
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.42B
Earnings Per Share (EPS)
5.37
TTM Avg
-2.79
3Y Avg
-4.06
5Y Avg
-3.18
Market Cap
$1.39B
Earnings Per Share (EPS)
0.90
TTM Avg
0.79
3Y Avg
0.56
5Y Avg
0.48
Market Cap
$1.42B
Earnings Per Share (EPS)
-5.84
TTM Avg
-6.06
3Y Avg
-7.62
5Y Avg
-6.71
Market Cap
$1.37B
Earnings Per Share (EPS)
-8.88
TTM Avg
53.77
3Y Avg
24.70
5Y Avg
19.33
Market Cap
$1.44B
Earnings Per Share (EPS)
-0.44
TTM Avg
-0.04
3Y Avg
-0.09
5Y Avg
-0.12
Market Cap
$1.45B
Earnings Per Share (EPS)
1.71
TTM Avg
0.68
3Y Avg
0.58
5Y Avg
0.72
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | $1.40B | -0.42 | -0.35 | -1.36 | -2.02 |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | N/A | -1.26 | -1.26 | -1.26 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 5.37 | -2.79 | -4.06 | -3.18 |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 0.90 | 0.79 | 0.56 | 0.48 |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.42B | -5.84 | -6.06 | -7.62 | -6.71 |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | -8.88 | 53.77 | 24.70 | 19.33 |
| Certara, Inc. (CERT)vs › | $1.44B | -0.44 | -0.04 | -0.09 | -0.12 |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 1.71 | 0.68 | 0.58 | 0.72 |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | -2.74 | -3.05 | -2.66 | -2.66 |
Trailing EPS (TTM)
$-0.42
Forward EPS (Est.)
$-0.50
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.34 |
| 2024-12-31 | -0.36 |
| 2023-12-31 | -0.96 |
| 2022-12-31 | -3.78 |
| 2021-12-31 | -4.64 |
| 2019-12-31 | -0.03 |
